vTv Therapeutics Inc
NASDAQ:VTVT

Watchlist Manager
vTv Therapeutics Inc Logo
vTv Therapeutics Inc
NASDAQ:VTVT
Watchlist
Price: 13.5723 USD -1.71% Market Closed
Market Cap: 40.9m USD
Have any thoughts about
vTv Therapeutics Inc?
Write Note

vTv Therapeutics Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

vTv Therapeutics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
vTv Therapeutics Inc
NASDAQ:VTVT
Depreciation & Amortization
$87k
CAGR 3-Years
-1%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.4B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
$5.6B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$219.7m
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$469.5m
CAGR 3-Years
20%
CAGR 5-Years
19%
CAGR 10-Years
25%
No Stocks Found

vTv Therapeutics Inc
Glance View

Market Cap
43.3m USD
Industry
Biotechnology

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 9 full-time employees. The company went IPO on 2015-07-30. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

VTVT Intrinsic Value
5.9179 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is vTv Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
87k USD

Based on the financial report for Sep 30, 2024, vTv Therapeutics Inc's Depreciation & Amortization amounts to 87k USD.

What is vTv Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-8%

Over the last year, the Depreciation & Amortization growth was -3%. The average annual Depreciation & Amortization growth rates for vTv Therapeutics Inc have been -1% over the past three years , -8% over the past five years .

Back to Top